Biotech | April 06, 2022
BioFluidica to introduce next-generation biomarker isolation platform
BioFluidica LiquidScan harnesses the power of microfluidics
BioFluidica LiquidScan harnesses the power of microfluidics
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Recommendation is based on pivotal data from the phase III POLARIX study
The test can overcome the time and cost limitations of traditional culture-based drug susceptibility testing as it can more rapidly detect all mutations known to be associated with drug resistance for any TB drug in one step
Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
The initiative brings internationally eminent cardiologists to increase awareness of health screening tests amongst pre-menopausal women
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Subscribe To Our Newsletter & Stay Updated
